Closer Look
Alnylam's plea patience is working out
Shares of Alnylam Pharmaceuticals fell about 10% earlier this month after the company made some 11th-hour changes to an all-important Phase 3 study. The company has spent the last week or so making its case for why those late-inning amendments are not cause for alarm, and, at least according to the stock price, it's working.
As STAT's Adam Feuerstein writes, Alnylam has almost fully recovered since it first disclosed a delay to Helios-B, a study testing whether the RNA-interference therapy called vutrisiran can improve the lives of patients with the progressive heart disease ATTR-CM.
According to CEO Yvonne Greenstreet, the company made its decision after seeing longer follow-up data on the outcomes of people with ATTR-CM treated with another Alnylam medicine called patisiran, along with late-stage study results presented by BridgeBio on its competing treatment for ATTR-CM called acoramidis. "Everything we've seen actually makes us very confident about the study delivering its outcome," Greenstreet said.
Read more.
Regulatory
The FDA isn't afraid to yank a disappointing drug
The FDA is rescinding its approval of a blood cancer treatment from the Swedish firm Oncopeptides, the agency's first exercise of a new authority that allows regulators to more quickly withdraw drugs that have not lived up to their promise.
The decision concludes a seven-month process that began after Oncopeptides' drug, which won accelerated approval in 2021, failed in a Phase 3 study meant to confirm its observed benefits. The FDA moved to rescind approval of the drug, called Pepaxto, and Oncopeptides appealed. In a letter issued Friday, Peter Marks, head of the agency's biologics division, overruled the company's arguments and ordered the withdrawal of Pepaxto. In a statement, Oncopeptides said it will "thoroughly assess the decision."
The move comes amid increased scrutiny of the FDA's accelerated approval program, which allows novel drugs to reach the market based on preliminary signs of efficacy while larger trials continue. Public health advocates have argued that drug companies abuse the system, pointing out that it takes nearly four years for ineffective drugs to have their accelerated approvals withdrawn.
Public health
The next flu vaccines will look familiar
The World Health Organization issued recommendations Friday on which flu viruses the next vaccine should target. There was good news for manufacturers: People in the Northern Hemisphere will get the same flu shot next winter that people in the Southern Hemisphere are getting to prepare for their upcoming flu season. In fact, the component of the vaccine that targets the flu B Victoria lineage has been unchanged since the 2022 vaccine for the Southern Hemisphere.
Why is this good for manufacturers? Learning to optimize growth of a new virus can take time. Since they have worked extensively with these viruses, manufacturers will know how to grow them.
In its report, the WHO reiterated it would like manufacturers to make trivalent vaccines, containing only viruses targeting influenza A viruses H1N1 and H3N2 plus B/Victoria. But it acknowledged some national regulatory agencies may not be ready to move away from quadrivalent formulations, which also target seemingly extinct B/Yamagata viruses.
The Food and Drug Administration's vaccine advisory committee will meet March 5 to formalize the formulation for next winter for the U.S.
No comments